|
Jun 13
|
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
|
|
May 15
|
PLX: First Quarter Update
|
|
May 13
|
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 11
|
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
|
|
May 3
|
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
|
|
Mar 15
|
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
PLX: Elfabrio Geographic Expansion
|
|
Mar 14
|
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
|
|
Mar 14
|
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
|
|
Mar 7
|
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
|
|
Feb 23
|
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
|
|
Nov 30
|
Levicept Appoints Eliot Forster as CEO
|
|
Aug 8
|
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript
|
|
Aug 8
|
PLX: Second Quarter Results
|
|
Aug 7
|
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
|
|
May 4
|
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
|
|
Apr 27
|
Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023
|